Elizabeth A. McMillan
Pfizer (United States)(US)Université Bourgogne Franche-Comté(FR)
Publications by Year
Research Areas
RNA modifications and cancer, Cancer Mechanisms and Therapy, Cancer-related gene regulation, RNA Research and Splicing, Computational Drug Discovery Methods
Most-Cited Works
- → Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets(2015)1,143 cited
- → Metabolic Heterogeneity in Human Lung Tumors(2016)1,115 cited
- → Correction: Corrigendum: The OncoPPi network of cancer-focused protein–protein interactions to inform biological insights and therapeutic strategies(2017)644 cited
- → LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer(2018)474 cited
- → Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells(2019)229 cited
- → The OncoPPi network of cancer-focused protein–protein interactions to inform biological insights and therapeutic strategies(2017)219 cited
- → XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer(2016)208 cited
- → Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor(2021)172 cited
- → Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer(2013)171 cited
- → Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan(2017)153 cited